Source link : https://www.newshealth.biz/health-news/fda-oks-mesenchymal-stromal-cell-therapy-for-gvhd/
The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-vs-host disease (SR-aGVHD) in children 2 months of age or older. It’s the first MSC product approved by the FDA for any indication. According to a new release from the […]
Author : News Health
Publish date : 2024-12-19 18:45:56
Copyright for syndicated content belongs to the linked Source.